reduce insulin dose when starting glp-1 receptor agonist Drugs and Type 1 Diabetes: Less Insulin, Better Time in Range — What the Evidence How Much GLP-1 Do You

(2013) provided an early indication in rodents, primates, and humans that combining GLP-1R and GIPR agonists could be more effective than administering GLP-1RA alone

For instance, in January 2025, the FDA approved semaglutide (Ozempic) as a medication to reduce the risk of kidney failure, kidney disease progression, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease (CKD)

doi:10.1007/s10557-023-07456-x 33

Intraperitoneal injection of the pancreatic peptide amylin potently reduces behavioral impairment and brain amyloid pathology in murine models of Alzheimers disease

Obesity is associated with numerous cardiometabolic complications and contributes to increased overall mortality [4, 5]

In a study on Medicaid recipients, Jerrell found that black children with obesity had more diagnosed medical conditions but received less health care than non-black children [213]